Anlon Healthcare Limited has informed the exchange about the Share Swap Agreement ("SSA").

August 08, 2026 To, To, Listing Department, The National Stock Exchange of India BSE Limited Ltd. Phiroze Jeejeebhoy Towers, The Listing Department Dalal Street, Exchange Plaza, Mumbai – 400 001 Bandra – Kurla Complex, Ref: BSE Scrip Code: 544497 Mumbai – 400051, NSE Scrip Code: AHCL Sub: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation, 2015 (“SEBI Listing Regulations”) Respected Sir/Madam, Pursuant to Regulation 30 read with Part - A of Schedule III of SEBI Listing Regulations, and with reference to our earlier intimation of Board Meeting held on Thursday, July 30, 2026, the Company has executed today i.e., Saturday, August 08, 2026, (a) the Share Swap Agreement (“AOPL SSA”) with certain shareholders of Apiqo Organics Private Limited (“AOPL”) with the intention to acquire up to 32.52% shareholding in AOPL; and (b) the Share Swap Agreement (“BLPL SSA”) with certain shareholders of Bizotic Lifescience Private Limited (“BLPL SSA”), with the intention to acquire up to 43.33% shareholding in BLPL, in both the cases, in lieu of issuance and allotment of the fresh equity shares of the Company on a preferential basis for consideration other than cash, to such selling shareholders, subject to necessary approvals. The Annexures herein contains details pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations and additional details as required under the SEBI Master Circular for compliance with the provisions of the Listing Regulations by listed entities, bearing ref. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. You are requested to take the above information on your record. Thanking You. For ANLON HEALTHCARE LIMITED PUNITKUMAR RASADIA MANAGING DIRECTOR DIN: 06696258 ANLON HEALTHCARE LIMITED CIN No.: U24230GJ2013PLC077543 REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot- 360005, Gujarat (INDIA) PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in ANNEXURE-A Details required under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 Sr Particulars Description 1 Name of the target entity, details in brief Name: Apiqo Organics Private such as size, turnover etc.; Limited (“AOPL”) (CIN: U21001GJ2025PTC169863) is an Indian private limited company, incorporated on December 1, 2025, by way of conversion from the partnership firm to a private limited company. Brief details: AOPL is inter alia engaged in manufacturing pharmaceutical intermediate, industrial and fine chemicals and inorganic chemicals, Turnover: Rs.7,254.11 /- Lakh (as on 31.03.2026) and Rs.4,554.36 /- Lakh (as on 30.06.2026) 2 Whether the acquisition would fall within The acquisition qualifies as a related party transaction(s) and whether Related Party Transaction under the the promoter/ promoter group/ group SEBI (Listing Obligations and companies have any interest in the entity Disclosure Requirements) being acquired? If yes, nature of interest Regulations, 2015, as promoters and details thereof and whether the same and some of the directors are is done at “arm’s length”; common in both entities. The promoter(s), promoter group or group companies have interest in the entity whose shareholding is proposed to be acquired. The transaction is being undertaken pursuant to the terms and conditions of the AOPL SSA executed between the parties and is on an arm's length basis. 3 Industry to which the entity being Pharmaceuticals acquired belongs; 4 Objects and impact of acquisition The acquisition of further shares of (including but not limited to, disclosure of AOPL is made with an objective to reasons for acquisition of target entity, if strengthen the supply of critical its business is outside the main line of materials for the Company, achieve business of the listed entity); strategic synergies, and enhance long-term shareholder value. ANLON HEALTHCARE LIMITED CIN No.: U24230GJ2013PLC077543 REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot- 360005, Gujarat (INDIA) PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in 5 Brief details of any governmental or In principle, listing and trading regulatory approvals required for the approval of the stock exchanges acquisition; shall be required for listing of the shares to be issued pursuant to preferential issue. 6 Indicative time period for completion of The proposed acquisition is subject the acquisition; to completion of certain customary closing conditions under the AOPL SSA and is expected to be completed within 90 days from the date of signing of the AOPL SSA or by such other timelines as may be mutually agreed between the parties 7 Consideration - whether cash The transaction is proposed to be consideration or share swap or any other effected through a share swap form and details of the same; agreement pursuant to which equity shares of the Company shall be issued and allotted to the shareholders of AOPL, in consideration for acquisition of their equity shares held in AOPL, subject to applicable laws and approvals. No cash consideration is expected to be payable. 8 Cost of acquisition and/or the price at The consideration shall be which the shares are acquired; discharged by issuance of equity shares of the Company in accordance with the agreed share exchange ratio/ swap ratio. The aggregate consideration is approximately Rs. 1,165,179,600/-, subject to customary adjustments, if any. Cost of acquisition: Rs. 1,165,179,600/- Price at which shares are acquired: Up to 45,16,200 equity shares at price of Rs.258/- each aggregating Rs. 1,165,179,600/-. 9 Percentage of shareholding / control Percentage of shareholding acquired and / or number of shares acquired: The Company expects to acquired; acquire up to 32.52% shareholding in AOPL, subject to acceptance of share swap proposal by all the shareholders of AOPL. ANLON HEALTHCARE LIMITED CIN No.: U24230GJ2013PLC077543 REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot- 360005, Gujarat (INDIA) PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in Control acquired: Not applicable pursuant to the proposed transaction. Number of shares acquired: Up to 45,16,200 equity shares of the Target Company. 10 Brief background about the entity Brief background: Please refer (1) acquired in terms of products/line of above. business acquired, date of incorporation, history of last 3 years turnover, country Country in which the acquired entity in which the acquired entity has presence has presence: India and any other significant information (in brief); Turnover for the last 3 years: Financial Year Amt. in Lakh 2023-24 Rs.1,711.10 2024-25 Rs.977.78 2025-26 Rs.7,254.11 ANLON HEALTHCARE LIMITED CIN No.: U24230GJ2013PLC077543 REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot- 360005, Gujarat (INDIA) PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in ANNEXURE-B Details required under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 Sr Particulars Description 1 Name of the target entity, details in brief Name: Bizotic Lifescience Private such as size, turnover etc.; Limited (“BLPL”) (CIN: U33111GJ2015PTC082917) is an Indian private limited company, incorporated on April 17, 2015. Brief details: BLPL is inter alia engaged in the business of manufacturing, supplying and exporting pharmaceutical drugs and intermediates, industrial and fine chemicals, more specifically, active pharmaceutical ingredients (API) including providing contract research and manufacturing services. Turnover: Rs.3,126.64 /- Lakh (as on 31.03.2026) and Rs.1152.78 /- Lakh (as on 30.06.2026) 2 Whether the acquisition wou [Showing first 8,000 characters — download PDF for full document]